Treatment of hepatocellular carcinoma with adriamycin.Preliminary communication
- 1 October 1975
- Vol. 36 (4), 1250-1257
- https://doi.org/10.1002/1097-0142(197510)36:4<1250::aid-cncr2820360410>3.0.co;2-x
Abstract
In a Phase II clinical trial, 14 patients with histologically proven primary hepatocellular carcinoma were treated with adriamycin administered intravenously at a dose of 75 mg/m2 every 3 weeks. All 11 evaluable patients responded with 3 exhibiting complete tumor regression after two, three, and five courses of adriamycin respectively. The remission durations for these 3 were 3, 6, and 7 months, and their survivals were 8, 9, and 13 months, respectively. The median survival of the evaluable patients is 8 months (range 1–13 months). The side effects encountered included myelosuppression, anorexia, nausea, vomiting, and alopecia. Adriamycin seems to be an effective agent in hepatocellular carcinoma. Further trials are underway to test its true efficacy both singly and in combination with other drugs in the management of this tumor.Keywords
This publication has 11 references indexed in Scilit:
- Phase II evaluation of adriamycin in human neoplasiaCancer, 1973
- Adriamycin—an antitumor antibiotic in the treatment of neoplastic diseasesCancer, 1973
- Tumours of Liver, Biliary System and PancreasPublished by Springer Science and Business Media LLC ,1973
- One-Second Biopsy of the Liver — Problems of Its Clinical ApplicationNew England Journal of Medicine, 1970
- Survival after liver resection for cancerCancer, 1970
- Malignant hepatoma in the BantuCancer, 1970
- Infusion of liver tumours.BMJ, 1968
- Hepatic Artery Infusion Chemotherapy in HepatomaBMJ, 1968
- Pituitary Destruction by Injection of Radioactive Substance and Section of the Pituitary Stalk for Advanced CancerBritish Journal of Cancer, 1957
- The Clinical Problem of Primary Carcinoma of the LiverGastroenterology, 1954